Recently, Ma et al. also developed a potent LATS inhibitor, VT02956, which is able to reduce ESR1 expression and the growth of ER + breast cancer cell lines and patient-derived tumor organoids [119]. The gene discussed is ESR1; the disease is breast carcinoma.